Latest Schedule 13G passive stakes

Sands Capital entities and Frank M. Sands jointly report beneficial ownership of 5.3% of Acrivon Therapeutics' common stock as of June 30, 2026.

AQR Capital Management entities report beneficial ownership of 5.99% of Keystone Acquisition Corp.'s Class A ordinary shares as of June 30, 2026.

AQR Capital Management, through its subsidiaries, has reported beneficial ownership of 6.26% of Velos Acquisition I Corp.'s Class A Ordinary Shares as of June 30, 2026.

Invus Public Equities, L.P. and affiliated entities have reported beneficial ownership of 9.4% of Nanobiotix S.A.'s ordinary shares, including shares issuable from warrants.

AQR Capital Management, LLC, AQR Capital Management Holdings, LLC, and AQR Arbitrage, LLC collectively report beneficial ownership of 1,219,750 Class A ordinary shares, representing 5.87% of the class, in NewHold Investment Corp IV.

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have reported a change in their beneficial ownership of Rubrik, Inc. Class A Common Stock.

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have reported an increased beneficial ownership of MarketAxess Holdings Inc. common stock, now holding 5.59% of the class.

A filing reveals that Invus Public Equities, L.P. and affiliated entities now collectively beneficially own 7.0% of Silence Therapeutics plc's ordinary shares.

Centiva Capital, LP and its general partner, Centiva Capital GP, LLC, have filed a Schedule 13G amendment indicating they beneficially own 0% of SUMA Acquisition Corporation's Class A ordinary shares.

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have filed an amendment to their Schedule 13G, reporting a beneficial ownership of 6.64% in Kyndryl Holdings, Inc.

Centiva Capital, LP and Centiva Capital GP, LLC have updated their beneficial ownership filing for ProCap Acquisition Corp, now holding 1.50% of the Class A ordinary shares.

Invus Public Equities, L.P. and affiliated entities have reported beneficial ownership of 8.0% of Scholar Rock Holding Corporation's common stock as of June 30, 2026.

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have filed a Schedule 13G, reporting beneficial ownership of 5.01% of Huntsman Corp's common stock.

Rosalind Advisors Inc. and its affiliated entities have reported beneficial ownership of 9.9% of Regentis Biomaterials Ltd.'s common shares, primarily through warrants and existing shares.

Several entities affiliated with Invus Group and Raymond Debbane have collectively acquired a 6.0% stake in Abivax S.A., signaling a notable investment in the biopharmaceutical company.

Several Artal Group entities have updated their beneficial ownership filings for CAVA Group, Inc., reporting a 5.6% stake as of June 30, 2026.

Trium Capital LLP has disclosed beneficial ownership of 5.3% of RE/MAX Holdings, Inc. Class A Common Stock, signaling institutional interest.

Rosalind Advisors Inc. and related entities have reported beneficial ownership of 9.6% of Fennec Pharmaceuticals Inc. common shares as of June 30, 2026.

AQR Capital Management reports a beneficial ownership stake of 5.07% in Genpact LTD as of June 30, 2026.

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have filed an amendment to their Schedule 13G, reporting their beneficial ownership of Gartner Inc. common stock.

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, has disclosed a beneficial ownership of 125,261 shares, representing 9.99% of Silo Pharma, Inc.'s common stock.

Reporting Persons Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC have disclosed beneficial ownership of 0% of Silexion Therapeutics Corp's ordinary shares as of June 30, 2026.

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, have filed an amended Schedule 13G, reporting beneficial ownership of 9.99% of Sunshine Biopharma Inc. common stock.

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, has disclosed beneficial ownership of approximately 8.2% of PowerCompute, Inc.'s common stock.

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have filed an amendment to their Schedule 13G, reporting beneficial ownership of 7.21% of eHealth, Inc. common stock as of June 30, 2026.

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, has reported beneficial ownership of approximately 9.0% of Longeveron Inc.'s Class A Common Stock.

Reporting persons, including Intracoastal Capital LLC, have adjusted their beneficial ownership of GeoVax Labs, Inc. common stock to 4.99%, triggering a Schedule 13G filing.

GRI Bio, Inc. reports a beneficial ownership update from Intracoastal Capital LLC and associated individuals, holding just under 5% of the company's common stock.

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, has reported a beneficial ownership of 3.5% of Cemtrex Inc.'s common stock as of June 30, 2026, primarily through a warrant.

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, reported a combined beneficial ownership of 4.8% in Artelo Biosciences, Inc. common stock as of June 30, 2026.